Basel, December 8, 2016 - Novartis today announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...
New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide ® * to Ultibro ® Breezhaler ® improved lung function and was well tolerated. The FLASH study is the first ...
· Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients · Data from the pragmatic CRYSTAL ...
Basel, November 27, 2017 - Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic ...
Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the 2017 GOLD ...
(RTTNews) - Novartis (NVS) announced Monday positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive ...
The FINANCIAL — Novartis on December 8 announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...
The superiority of once-daily Ultibro Breezhaler over twice-daily salmeterol/fluticasone in improving lung function and reducing the rate of COPD exacerbations has been established in previous studies ...
Novartis has announced positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD ...
New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide®* to Ultibro® Breezhaler® improved lung function and was well tolerated. The FLASH study is the first randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results